Wegovy sales took a hit this year. Novo's CEO blames off-brand competition
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or compounded, versions of the treatment, according to the Danish pharma giant’s CEO Lars Fruergaard Jørgensen.Read more...
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or compounded, versions of the treatment, according to the Danish pharma giant’s CEO Lars Fruergaard Jørgensen.
